Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.1.24 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Eric Wang and 5 co-authors. Institution: Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada. Major MEDLINE topics: Diabetic Retinopathy, RNA, Long Noncoding, RNA, Small Interfering, Gene Silencing. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Purpose
Diabetic retinopathy (DR), a major cause of blindness in working-age adults, is driven by vascular dysfunction mediated by various angiogenic regulators. Although anti-VEGF therapies reduce vision impairment in some patients, they have limitations that leave room for novel treatments. The long non-coding RNA (lncRNA) HOX transcript antisense intergenic RNA (HOTAIR), which is upregulated in the retina in diabetes and regulates a range of factors including VEGF, contributes to DR pathology. Silencing HOTAIR prevents the dysregulation of VEGF and other factors. We explored targeting HOTAIR using siRNA conjugated to n-acetylgalactosamine (GalNAc) moieties for retinal delivery as a means of preventing diabetes-associated pathology in the retina.
Methods
GalNAc-modified siHOTAIR was evaluated in human retinal endothelial cells in vitro and using various models in vivo. The effects of GalNAc-modified siHOTAIR were assessed on the RNA, protein, and functional levels.
Results
GalNAc-modified siHOTAIR effectively entered retinal endothelial cells in vitro, and inhibited glucose-induced endothelial dysfunction by blocking multiple factors, including VEGF-A. GalNAc-siRNA localized to the retina in vivo following topical delivery, and prevented diabetes-induced pathological retinal changes with efficacy comparable to intravitreal injection.
Conclusions
GalNAc-modified siHOTAIR thus represents a potential therapeutic strategy that not only inhibits VEGF but also targets other pathogenic mediators regulated by HOTAIR, potentially offering broader efficacy than anti-VEGF monotherapy. Furthermore, it achieves this via noninvasive, topical delivery, circumventing the need for intravitreal injections required by current treatments. Thus, with further development, GalNAc-modified siHOTAIR may become an overall better approach to treating DR.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
- i-RNA Corporation, London, Ontario, Canada.
Cite
APA
Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026). Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.24
Vancouver
Wang E, Feng B, Chen S, Wang H, Ling T, Chakrabarti S. Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.24
BibTeX
@article{Wang2026,
author = {Wang, Eric and Feng, Biao and Chen, Shali and Wang, Honglin and Ling, Ting and Chakrabarti, Subrata},
title = {Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.1.24}
}
EUVIMED